Parameswari Singh

Lead the analytical stream on expression analytics (Jan 2025–Present), managing analytical experts and coordinating projects across stage-gates from research through clinical development.

- Led upstream process development and cell line development for cell & gene therapy products (2019–2024), integrating team, project, CMC, and technology-transfer management. - Led stable cell line development from transfection through clonal stable cell line generation, RCB development, and progression to MCB. - Established and optimized upstream processes across adherent and suspension cell systems (small-scale to large scale) supporting pre-IND/IND activities and material supply for Cell Manufacturing an

Cell and gene therapy, cell line development from transfection to clone screening, Lentivirus process development and optimisation - adherent and suspension processes, cell manufacturing for gene editing, CDMO, Subject Matter Expert for Technology Transfers of both processes and cell line development

- Managed neuro-oncology research projects in recombinant cell and gene therapy. - Identified novel targets through gene overexpression/knockout, functional genomics, and high-throughput sequencing. - Presented scientific findings, supervised students and technical assistants, and supported proposal development and competitive funding acquisition.

- Conducted translational research on stem cells and bone remodeling to identify novel bone biomaterials for surgical applications. - Research lab rotation, Comprehensive Cancer Center (CCC), Columbus, Ohio, USA (Jan–Mar 2013): epigenetics of lymphoid malignancies (Burkitt lymphoma, chronic lymphocytic leukemia).

Research on FMCG, assay development and validation, product evaluation, co-ordination of interdisciplinary teams, collaboration with external research partners